IO Biotech, Inc. - Common Stock (IOBT)

About IO Biotech, Inc. - Common Stock (IOBT)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

IO Biotech, Inc. - Common Stock News